Dr Reddy's Laboratories To Buy IP Rights Of Anti-Coagulant Drug For $17.5M

by Shirley Johanna on  September 26, 2015 at 10:51 AM Drug News
RSS Email Print This Page Comment
Font : A-A+

Australian drug discovery and development company Alchemia entered into a $17.5 million agreement with Dr Reddy's laboratories for exclusive intellectual property rights for anti-coagulant drug.
Dr Reddy's Laboratories To Buy IP Rights Of Anti-Coagulant Drug For $17.5M
Dr Reddy's Laboratories To Buy IP Rights Of Anti-Coagulant Drug For $17.5M

The sale is conditional on shareholder approval, as the sale constitutes a disposal of the company's main undertaking as per ASX listing rules, said the statement by Alchemia.

An anti-coagulant drug, fondaparinux sodium is generic version of Arixtra drug and has been approved by US and Europe for treating deep vein thrombosis and pulmonary embolism, it added.

Alchemia markets Fondaparinux in the US and other markets through partner Dr. Reddy Laboratories, the statement added.

Source: IANS

Post a Comment

Comments should be on the topic and should not be abusive. The editorial team reserves the right to review and moderate the comments posted on the site.
Notify me when reply is posted
I agree to the terms and conditions

More News on:

Drug Toxicity Signature Drug Toxicity 

News A - Z

A B C D E F G H I J K L M N O P Q R S T U V W X Y Z

News Search

Medindia Newsletters

Subscribe to our Free Newsletters!

Terms & Conditions and Privacy Policy.

Advertisement
Advertisement

Stay Connected

  • Available on the Android Market
  • Available on the App Store

Facebook

News Category

News Archive